Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation-Reference-Cited by-同舟云学术

Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation

Published:2017-06-08 Issue: Volume:8 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Woillard Jean-Baptiste,Mourad Michel,Neely Michael,Capron Arnaud,van Schaik Ron H.,van Gelder Teun,Lloberas Nuria,Hesselink Dennis A.,Marquet Pierre,Haufroid Vincent,Elens Laure

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference59 articles.

1. A new CYP3A5∗3 and CYP3A4∗22 cluster influencing tacrolimus target concentrations: a population approach.;Andreu;Clin Pharmacokinet.,2017

2. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.;Anglicheau;J. Am. Soc. Nephrol.,2003

3. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.;Asberg;Transpl. Int.,2013

4. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.;Benkali;Clin. Pharmacokinet.,2009

5. Statistical properties of single-marker tests for rare variants.;Bigdeli;Twin Res. Hum. Genet.,2014

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Effect of Cytochrome P450 Family 3 Subfamily A Member 5 (CYP3A5) Genetic Variants in Tacrolimus Dose Determination in Indian Renal Transplant Patients;ACS Pharmacology & Translational Science;2024-08-13

2. A joint population pharmacokinetic model to assess the high variability of whole-blood and intracellular tacrolimus in early adult renal transplant recipients;International Immunopharmacology;2024-08

3. Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients. Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration-dose ratio;Nefrología (English Edition);2024-03

4. CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach;Pharmaceutics;2023-11-29

5. A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction;Kidney International;2023-10